China’s CDE Releases Draft Guidelines for Decentralized Trials in Rare Disease Drug Development
China’s Center for Drug Evaluation (CDE) has released draft “Technical Guidelines for the Application of...
AbbVie Sues to Protect Rinvoq from Generic Competition in the US Market
AbbVie (NYSE: ABBV) has initiated legal action in the US to safeguard its blockbuster drug...
Novo Nordisk Sets February 2024 Launch for Wegovy in Japan, Expanding into Asia
Novo Nordisk (CPH: NOVO-B), headquartered in Denmark, has announced that it will launch its anti-obesity...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for Phase Ib/II Study of Dalpiciclib and HRS-8080
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it received approval from...
Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
Simcere Pharmaceutical Secures Rights to Develop Rademikibart in China
China’s Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into an agreement to acquire the...
Bayer Invests USD 130 Million in Parenteral Drugs Manufacturing Site in Germany
Bayer (ETR: BAYN) has inaugurated a new state-of-the-art parenteral drugs manufacturing site at its German...
Novo Nordisk Invests DKK 16 Billion to Expand French Production Facility
Denmark-based pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has initiated an expansion of its production facility...
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...
European Commission Proposes Overhaul of Pharmaceutical Legislation
The European Commission (EC) is advancing an update to Europe’s 20-year-old pharmaceutical legislation, with the...
Pyrotech Biotechnology’s PTT-936 Gets US FDA Clinical Trial Approval
Pyrotech (Beijing) Biotechnology Co., Ltd, a China-based biotech firm, has announced that it has received...
Boehringer Ingelheim and Eli Lilly’s Jardiance Receives NMPA Approval for CKD Treatment
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced that their SGLT2 inhibitor, Jardiance...
Zhejiang Huanqing Medical Technology Secures Series A Financing for Heart Failure Innovations
Zhejiang Huanqing Medical Technology Co., Ltd, a Chinese specialist in heart failure solutions, has reportedly...
Boehringer Ingelheim and Eli Lilly Secure NMPA Approval for Jardiance in Chronic Kidney Disease
Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have announced the receipt of marketing approval...
True Health Secures Over RMB 100 Million in Series B+ Financing for Surgical Robot Development
True Health, a Guangdong-based surgical robot developer backed by Gree Group, has reportedly raised over...
MicuRx Pharmaceuticals Secures NMPA Approval for MRX-4 and Contezolid Combination Therapy
Sino-US firm MicuRx Pharmaceuticals Inc. has announced that it has received clinical trial approval from...
Stada Arzneimittel AG Partners with CR Sanjiu for Distribution in China
Germany-based Stada Arzneimittel AG has announced a strategic distribution and promotion partnership with China’s state-owned...
C2 Pharma Secures C-DMF Approval for Pilocarpine Nitrate API
Ireland-based C2 Pharma has announced the receipt of approval for a C-DMF (drug master file)...
SCG Cell Therapy’s SCG101 Receives Tacit Approval for Cholangiocarcinoma Clinical Trial in China
China’s Center for Drug Evaluation (CDE) website has indicated that SCG Cell Therapy Pte. Ltd’s...
Akeso Biopharma’s Cadonilimab Meets Primary Endpoint in Phase III Cervical Cancer Study
China-based Akeso Biopharma (HKG: 9926) has announced that its Phase III AK104-303 study for cadonilimab...